3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
328
Fallopian Tube Neoplasms
153
Carcinoma, Ovarian Epithelial
115
Endometrial Neoplasms
95
Uterine Cervical Neoplasms
80
Neoplasms
28
Breast Neoplasms
27
Peritoneal Neoplasms
24
Brenner Tumor
24
Carcinoma, Non-Small-Cell Lung
21
Stomach Neoplasms
18
Recurrence
17
Neoplasm Metastasis
14
Uterine Neoplasms
13
Testicular Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Colorectal Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
10
Lung Neoplasms
10
Melanoma
9
Testicular Germ Cell Tumor
8
Central Nervous System Neoplasms
8
Urinary Bladder Neoplasms
7
Triple Negative Breast Neoplasms
7
Esophageal Neoplasms
7
Carcinoma
7
Prostatic Neoplasms
6
Pancreatic Neoplasms
6
Neurotoxicity Syndromes
6
Carcinosarcoma
6
Interventions
anlotinib
2
niraparib
1
afuresertib
1
Paclitaxel
1
PHI-101
1
Gemcitabine
1
ALT-803
1
1-dodecylpyridoxal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Platinum-resistant Ovarian Cancer
×
Paclitaxel
×
Gynecologic
×
Clear all
NCT04374630
2025-09-10
PROFECTA-II
Laekna Limited
Phase 2
Completed
150 enrolled